Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors.
作者信息
Chin-Yee Benjamin, Solh Ziad, Hsia Cyrus
机构信息
Clinical fellow, Division of Hematology, Department of Medicine, Western University, London, Ont.
Assistant professor, Pathology and Laboratory Medicine, Western University, London, Ont.
出版信息
CMAJ. 2020 Oct 19;192(42):E1271. doi: 10.1503/cmaj.76686.
Abstract
摘要
相似文献
1
Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖协同转运蛋白2抑制剂所致红细胞增多症
CMAJ. 2020 Oct 19;192(42):E1271. doi: 10.1503/cmaj.76686.
2
Sodium-glucose cotransporter-2 inhibitor-associated erythrocytosis: A retrospective cohort study.钠-葡萄糖协同转运蛋白2抑制剂相关红细胞增多症：一项回顾性队列研究。
J Intern Med. 2024 Jan;295(1):103-105. doi: 10.1111/joim.13722. Epub 2023 Sep 20.
3
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.与钠-葡萄糖协同转运蛋白2抑制剂治疗相关的JAK2野生型红细胞增多症。
Blood. 2021 Dec 30;138(26):2886-2889. doi: 10.1182/blood.2021013996.
4
Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology.钠-葡萄糖协同转运蛋白2抑制剂的使用与红细胞增多症：风险评估及血液科转诊需求
Nephrol Dial Transplant. 2023 Nov 30;38(12):2670-2672. doi: 10.1093/ndt/gfad171.
5
Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases.同时使用睾酮和 SGLT2 抑制剂治疗时发生红细胞增多症的风险：来自两个临床病例的警示。
J Clin Endocrinol Metab. 2019 Mar 1;104(3):819-822. doi: 10.1210/jc.2018-01702.
6
Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases.钠-葡萄糖共转运蛋白 2 抑制剂治疗期间的显著红细胞增多症：两例报告。
Diabetes Res Clin Pract. 2020 Apr;162:108127. doi: 10.1016/j.diabres.2020.108127. Epub 2020 Mar 26.
7
SGLT2 Inhibitor-Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event.一名慢性心力衰竭患者出现的与SGLT2抑制剂相关的红细胞增多症：一种潜在的严重不良事件
Circ Heart Fail. 2023 Jul;16(7):e010613. doi: 10.1161/CIRCHEARTFAILURE.123.010613. Epub 2023 Jun 15.
8
Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.SGLT2 抑制剂在 2 型糖尿病中的心血管获益、与二甲双胍的相互作用以及红细胞增多症的作用：一项自身对照病例系列研究。
Cardiovasc Diabetol. 2022 Jun 3;21(1):92. doi: 10.1186/s12933-022-01520-w.
9
Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs.睾酮诱导的跨性别男性红细胞增多症：代谢综合征患病率上升及钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂药物处方治疗指征扩大所带来的挑战。
Best Pract Res Clin Endocrinol Metab. 2024 Sep;38(5):101930. doi: 10.1016/j.beem.2024.101930. Epub 2024 Aug 25.
10
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.血红蛋白水平及其变化的预测因素，重点关注钠-葡萄糖协同转运蛋白2抑制剂托格列净给药后的贫血和红细胞增多症。
Diabetes Obes Metab. 2022 Dec;24(12):2469-2473. doi: 10.1111/dom.14836. Epub 2022 Sep 12.
引用本文的文献
1
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study.射血分数降低的心力衰竭患者使用钠-葡萄糖协同转运蛋白2抑制剂治疗后的红细胞增多症发生率及血栓栓塞风险：一项基于全国登记的队列研究
Cardiovasc Diabetol. 2025 Aug 1;24(1):314. doi: 10.1186/s12933-025-02871-w.
2
Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study.钠-葡萄糖协同转运蛋白2抑制剂相关红细胞增多症的患病率及血栓形成风险：一项回顾性队列研究
Cardiovasc Diabetol. 2025 Jul 10;24(1):276. doi: 10.1186/s12933-025-02805-6.
3
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females.卡格列净可能会增加红细胞增多症男性患者的血栓栓塞事件，但不会增加女性患者的此类事件。
Blood Adv. 2025 Jul 8;9(13):3202-3212. doi: 10.1182/bloodadvances.2025016320.
4
Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review.药物性红细胞增多症的诊断、管理及预后：一项系统综述
Blood Adv. 2025 May 13;9(9):2108-2118. doi: 10.1182/bloodadvances.2024015410.
5
Cardiorenal syndrome: evolving concepts and pediatric knowledge gaps.心肾综合征：不断演变的概念及儿科知识空白
Pediatr Nephrol. 2025 Mar;40(3):651-660. doi: 10.1007/s00467-024-06517-z. Epub 2024 Sep 27.
6
Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.肾移植后移植后糖尿病的管理：治疗挑战与进展
Pharmaceuticals (Basel). 2024 Jul 26;17(8):987. doi: 10.3390/ph17080987.
7
Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review.安大略省西南部接受疑似真性红细胞增多症分子检测患者血红蛋白升高的次要原因：图表回顾。
CMAJ Open. 2022 Nov 8;10(4):E988-E992. doi: 10.9778/cmajo.20210322. Print 2022 Oct-Dec.
8
Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.SGLT2 抑制剂在 2 型糖尿病中的心血管获益、与二甲双胍的相互作用以及红细胞增多症的作用：一项自身对照病例系列研究。
Cardiovasc Diabetol. 2022 Jun 3;21(1):92. doi: 10.1186/s12933-022-01520-w.
9
Effects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review.饮食和抗高血糖药物对勃起功能障碍的影响：系统评价。
Andrology. 2023 Feb;11(2):282-294. doi: 10.1111/andr.13192. Epub 2022 May 13.
10
Recent advances in new-onset diabetes mellitus after kidney transplantation.肾移植术后新发糖尿病的最新进展。
World J Diabetes. 2021 May 15;12(5):541-555. doi: 10.4239/wjd.v12.i5.541.
本文引用的文献
1
Investigation and management of erythrocytosis.红细胞增多症的调查与处理
CMAJ. 2020 Aug 10;192(32):E913-E918. doi: 10.1503/cmaj.191587.
2
Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases.钠-葡萄糖共转运蛋白 2 抑制剂治疗期间的显著红细胞增多症：两例报告。
Diabetes Res Clin Pract. 2020 Apr;162:108127. doi: 10.1016/j.diabres.2020.108127. Epub 2020 Mar 26.
3
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.恩格列净对2型糖尿病合并冠状动脉疾病患者促红细胞生成素水平、铁储备及红细胞形态的影响
Circulation. 2020 Feb 25;141(8):704-707. doi: 10.1161/CIRCULATIONAHA.119.044235. Epub 2019 Nov 11.
4
Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases.同时使用睾酮和 SGLT2 抑制剂治疗时发生红细胞增多症的风险：来自两个临床病例的警示。
J Clin Endocrinol Metab. 2019 Mar 1;104(3):819-822. doi: 10.1210/jc.2018-01702.
5
Unmasking and aggravation of polycythemia vera by canagliflozin.卡格列净致真性红细胞增多症揭帽及加重。
Diabet Med. 2018 Nov;35(11):1613-1616. doi: 10.1111/dme.13706.
6
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.恩格列净如何降低心血管死亡率？来自 EMPA-REG OUTCOME 试验中介分析的见解。
Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.
7
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Zotero 插件